Dr. Belanoff’s financial interests in Corcept Therapeutics reflect a significant investment in the company’s future. In recent years, he received a grant of 500,000 stock options in 2023, but none of those options vested, focusing more on performance-linked compensation. His...

Dr. Belanoff’s financial interests in Corcept Therapeutics reflect a significant investment in the company’s future. In recent years, he received a grant of 500,000 stock options in 2023, but none of those options vested, focusing more on performance-linked compensation. His peak income came in 2021, when he earned over $100 million, largely due to the vesting of stock options tied to company performance. His compensation has shown fluctuations, with varying total earnings from $597,670 in 2015 to over $100 million in 2021, emphasizing the growth and success of Corcept under his guidance. His wealth is intricately linked with the company's success in developing and commercializing effective treatments, indicating a strong alignment of interests between him and shareholders.